Search

Search Results

1. Searching for airways biomarkers useful to identify progressive pulmonary fibrosis

   Background

   Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with unknown etiology. To date, the identification of new...

   Piera Soccio, Giorgia Moriondo, ... Donato Lacedonia in BMC Pulmonary Medicine

   Article Open access 26 October 2023
   

2. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics

   Introduction

   In the INBUILD trial in patients with progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (IPF), nintedanib slowed...

   Martin Kolb, Kevin R. Flaherty, ... Athol U. Wells in Advances in Therapy

   Article Open access 26 September 2023
   

3. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial

   Objectives

   Some patients with rheumatoid arthritis develop interstitial lung disease (RA-ILD) that develops into progressive pulmonary fibrosis. We...

   Eric L. Matteson, Martin Aringer, ... Martin Kolb in Clinical Rheumatology

   Article Open access 20 May 2023
   

4. Interstitial Lung Disease and Progressive Pulmonary Fibrosis: a World Trade Center Cohort 20-Year Longitudinal Study

   Purpose

   World Trade Center (WTC) exposure is associated with obstructive airway diseases and sarcoidosis. There is limited research regarding the...

   Krystal L. Cleven, Rachel Zeig-Owens, ... David J. Prezant in Lung

   Article Open access 07 May 2024
   

5. Progressive pulmonary fibrosis in a murine model of Hermansky-Pudlak syndrome

   Background

   HPS-1 is a genetic type of Hermansky-Pudlak syndrome (HPS) with highly penetrant pulmonary fibrosis (HPSPF), a restrictive lung disease...

   Shachar Abudi-Sinreich, Steven P. Bodine, ... May Christine V. Malicdan in Respiratory Research

   Article Open access 04 May 2022
   

6. Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial

   Background

   Lower body mass index (BMI) and weight loss have been associated with worse outcomes in some studies in patients with pulmonary fibrosis....

   Michael Kreuter, Elisabeth Bendstrup, ... Bruno Crestani in Respiratory Research

   Article Open access 09 March 2023
   

7. Clinical effect of progressive pulmonary fibrosis on patients with connective tissue disease-associated interstitial lung disease: a single center retrospective cohort study

   The concept of progressive pulmonary fibrosis (PPF) has been introduced to predict the diverse prognosis of interstitial lung disease (ILD). However,...

   Ju Kwang Lee, Yura Ahn, ... Ho Cheol Kim in Clinical and Experimental Medicine

   Article Open access 13 October 2023
   

8. Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease

   Objective

   Interstitial lung disease (ILD) is a common extramuscular manifestation of the anti-synthetase syndrome (ASS). Patients with ASS-ILD are at...

   Hongyan Fu, Ziyao Zheng, ... Juan Chen in Clinical Rheumatology

   Article Open access 17 March 2023
   

9. Interstitial Lung Abnormalities (ILA) and Pulmonary Fibrosis

   Purpose of Review

   This review identifies the similarities and differences between interstitial lung abnormalities (ILA) and pulmonary fibrosis in...

   Noriaki Wada, Kyung Soo Lee, Hiroto Hatabu in Current Pulmonology Reports

   Article 02 April 2024
   

10. Diagnosis of interstitial lung disease (ILD) secondary to systemic sclerosis (SSc) and rheumatoid arthritis (RA) and identification of ‘progressive pulmonary fibrosis’ using chest CT: a narrative review

    Interstitial lung disease (ILD) is a frequent manifestation of connective tissue diseases (CTDs), with incidence and prevalence variously assessed in...

    Antonio Poerio, Eleonora Carlicchi, Maurizio Zompatori in Clinical and Experimental Medicine

    Article 06 October 2023
    

11. Animal models of acute exacerbation of pulmonary fibrosis

    Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive scarring interstitial lung disease with an unknown cause. Some patients may experience...

    Xu Ye, Mingrui Zhang, ... Mengshu Cao in Respiratory Research

    Article Open access 25 November 2023
    

12. Clinical outcomes and risk factors of progressive pulmonary fibrosis in primary Sjögren’s syndrome-associated interstitial lung disease

    Background

    To investigate the clinical outcomes and risk factors associated with progressive fibrosing interstitial lung disease (PF-ILD) in patients...

    Yu-Hsuan Chen, Tai-Ju Lee, ... Jung-Yien Chien in BMC Pulmonary Medicine

    Article Open access 19 July 2023
    

13. Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders

    The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several degenerative diseases have...

    Vito D’Agnano, Domenica Francesca Mariniello, ... Fabio Perrotta in Drugs

    Article Open access 17 April 2024
    

14. Current state of signaling pathways associated with the pathogenesis of idiopathic pulmonary fibrosis

    Idiopathic Pulmonary Fibrosis (IPF) represents a chronic and progressive pulmonary disorder distinguished by a notable mortality rate. Despite the...

    Yang Zhou, Tingting Ling, Weihong Shi in Respiratory Research

    Article Open access 17 June 2024

15. Tuftelin1 drives experimental pulmonary fibrosis progression by facilitating stress fiber assembly

    Background

    Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) with unknown etiology, characterized by sustained...

    Caoyuan Niu, Kai Xu, ... Guoying Yu in Respiratory Research

    Article Open access 17 December 2023
    

16. Dexmedetomidine alleviates pulmonary fibrosis through the ADORA2B-Mediated MAPK signaling pathway

    Background

    Idiopathic pulmonary fibrosis (IPF) is a chronically progressive fibrotic pulmonary disease characterized by an uncertain etiology, a poor...

    **aofan Lai, Yingying Lin, ... Wenqi Huang in Respiratory Research

    Article Open access 29 August 2023
    

17. Metabolomic insights into pulmonary fibrosis: a mendelian randomization study

    Background

    This study leverages a two-sample Mendelian Randomization (MR) approach to explore the causal relationships between 1,400 metabolites and...

    Wuyinuo Tang, Huanyu Jiang, ... Lvyuan He in BMC Pulmonary Medicine

    Article Open access 06 June 2024
    

18. Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry

    Introduction

    Pulmonary fibrosis is a characteristic of various interstitial lung diseases (ILDs) with differing etiologies. Clinical trials in...

    Sarah E. Chang, Guiquan Jia, ... Margaret Neighbors in Lung

    Article Open access 16 May 2024
    

19. NR2F2 alleviates pulmonary fibrosis by inhibition of epithelial cell senescence

    Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal, and aging-associated interstitial lung disease with a poor prognosis and...

    Ruyan Wan, Siqi Long, ... Guoying Yu in Respiratory Research

    Article Open access 02 April 2024
    

20. CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis

    COVID‐19 patients can develop clinical and histopathological features associated with fibrosis, but the pathogenesis of fibrosis remains poorly...

    Jiao Wu, Liang Chen, ... Zhi-Nan Chen in Signal Transduction and Targeted Therapy

    Article Open access 25 November 2022